Loading
Vaccine Development / Neonatal Infection / BCG Vaccine · unknown
Human Vaccines & Immunotherapeutics · July 14, 2026
Raises a question worth testing. It does not answer one.
This narrative review proposes that BCG vaccine efficacy against tuberculosis and other diseases may be improved by changing administration from cutaneous to intravenous routes. The hypothesis is based on recent animal model evidence showing superior protection with intravenous BCG, but no human trial data or effect sizes are provided.
unknown. Patients receiving BCG vaccination for tuberculosis, bladder cancer, or neonatal sepsis prevention.
Recent animal model evidence indicates intravenous BCG provides superior protection compared to intradermal or subcutaneous routes BCG has been the only available TB vaccine for over 100 years despite suboptimal protection Potential applications extend beyond TB to bladder cancer and neonatal sepsis
No safety data for intravenous BCG administration in humans provided
The hypothesis that intravenous BCG administration may improve efficacy warrants human trial investigation, but current evidence from animal models is insufficient to change clinical practice. Existing standard routes (intradermal/subcutaneous) remain appropriate pending human efficacy and safety data.
Narrative review of evidence suggesting route of BCG administration affects efficacy, without original trial data or quantitative synthesis.
As stated by the source record.
The hypothesis that intravenous BCG administration may improve efficacy warrants human trial investigation, but current evidence from animal models is insufficient to change clinical practice. Existing standard routes (intradermal/subcutaneous) remain appropriate pending human efficacy and safety data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Tuberculosis (TB) is the single most deadly human pathogen and has been for centuries. BCG, a vaccine designed to protect from TB, is the most frequently administered vaccine in human history. Despite BCG's many shortcomings, which include suboptimal protection from TB, BCG has for over 100 y remained the only available vaccine in the fight against TB. Recent evidence from animal models indicates that BCG administered intravenously provides superior protection compared to cutaneous routes, such as intradermal or subcutaneous. Therefore, the route to improve success for BCG in the fight against TB and other illnesses, such as bladder cancer and neonatal sepsis, may simply relate to changing the route of its administration. We here trace the trajectory regarding the centrality of route of administration for BCG from its roots all the way to the most recent scientific breakthroughs, and with that illuminate a potential path ahead toward deploying BCG most optimally.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.